To investigate the application of radiochromic film LD-V1 for measuring the dose profile of wide detector CT and comparing the measurements with the console-displayed CTDI, with the aim of obtaining correction factors. Calibration curves in CTDI phantoms were first obtained with various tube currents at 120 kV. Then, at the selected wide beam collimations (80, 100, 120, 140, 160 mm), the film was placed in the extended phantom holes to obtain the dose profile. CTDI was calculated for different integration intervals, which allowed obtaining the CTDI measurement efficiency. Finally, the CTDI measured was compared to the console-displayed CTDI, and corresponding correction factors were derived. The discrepancy between the CTDI obtained by the calibration curve and ionization chamber was essentially in the range of -8-4%. The CTDI measurement efficiency was found to decrease with increasing beam widths. Furthermore, under selected wide beam collimations (80, 100, 120, 140, 160 mm), the correction factors in the head phantom were 1.299, 1.284, 1.157, 1.151, 1.099; 1.566, 1.585, 1.512, 1.365, 1.327 in the body phantom, respectively. Radiochromic film LD-V1 is feasible for measuring the dose profile of a wide detector CT scanner. The console-displayed CTDI doesn't provide a full assessment of the radiation dose. It is recommended that the correction factors obtained in this study be used to improve the accuracy for evaluating the radiation dose to the subject.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889078 | PMC |
http://dx.doi.org/10.1038/s41598-025-91681-x | DOI Listing |
Dermatol Reports
February 2025
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Naples.
Basal cell carcinoma (BCC) is the most common malignant tumor in white populations. Multiple studies demonstrated that the aberrant activation of Hedgehog signaling is a driver of BCC development, and its blockade represents a potential therapeutic target. In Italy, clinicians can prescribe Hedgehog inhibitors (HhIs) vismodegib and sonidegib.
View Article and Find Full Text PDFJAMA Netw Open
March 2025
Department of Cardiovascular Medicine, St Luke's International Hospital, Tokyo, Japan.
Importance: Despite growing criticism of alcohol consumption due to its overall health risks, it remains unknown how changes in alcohol consumption, particularly cessation, affect lipid profiles outside of intense interventions.
Objective: To clarify the association of alcohol initiation and cessation with subsequent changes in low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C).
Design, Setting, And Participants: This cohort study included individuals undergoing annual checkups at a center for preventive medicine in Tokyo, Japan, from October 2012 to October 2022.
Mesenchymal stem/stromal cells (MSCs) offer promising therapeutic potential in cell-based therapies for various diseases. However, the safety of genetically modified MSCs remains poorly understood. This study aimed to evaluate the general toxicity and safety of Wharton's Jelly-Derived MSCs (WJ-MSCs) engineered to express the antimicrobial peptide SE-33 in an animal model.
View Article and Find Full Text PDFIndian J Otolaryngol Head Neck Surg
January 2025
National Institute of Medical Science and Research, Jaipur, Rajasthan India.
Patients with squamous cell carcinoma of the head and neck (HNSCC) often present with advanced locoregional disease. Combined modality treatment with definitive concurrent chemoradiotherapy (CTRT) has become the standard of care for these cancers. We compared the efficacy and toxicity profile of weekly cisplatin regime compared to a three-weekly cisplatin regime in the setting of definitive CTRT for locally advanced HNSCC (LAHNSCC).
View Article and Find Full Text PDFFront Med (Lausanne)
February 2025
Department of Pharmacy, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
VV116 is an oral antiviral drug against SARS-CoV-2, known for its favorable efficacy and safety profile. But its application in patients with severe liver dysfunction has not been evaluated. Here, we report a case in which a patient with aplastic anemia and liver impairment (recovery phase of acute liver failure) was infected with SARS-CoV-2.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!